Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.38 |
| ▸ | CTSS | P25774 | 4/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6017833 | 0.91 | MAPT (0.36) | DRD2HTR7HTR2AHTR2CSYK | |
| SCHEMBL5037986 | 0.90 | DRD2 (0.34) | DRD2DRD3HTR7HTR2AHTR2C | |
| SCHEMBL6017851 | 0.90 | LMNA (0.39) | DRD4 | |
| SCHEMBL6017982 | 0.83 | TPSAB1 (0.32) | — | |
| SCHEMBL6017650 | 0.80 | MCHR1 (0.35) | DRD3 | |
| SCHEMBL5040951 | 0.79 | MMP2 (0.43) | DRD2CTSS | |
| SCHEMBL6017663 | 0.77 | HTR6 (0.38) | — | |
| SCHEMBL6017698 | 0.77 | ACE2 (0.31) | — | |
| SCHEMBL6017863 | 0.76 | NPY5R (0.33) | — | |
| SCHEMBL5033761 | 0.76 | CHEK1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041668-B2 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | CDKL3, CCNL2, CDKL1 | DRD2 1796/4885CTSS 2782/4885DRD3 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.